Table 2.
Baseline induced sputum cytology and inflammatory marker levels and before-after each treatment
| Variable | Baseline | Placebo | P value | Simvastatin | P value | ||
|---|---|---|---|---|---|---|---|
| Before | After | Before | After | ||||
| Sputum mediators | |||||||
| ADA mRNA (fold change) (n = 13) |
1.03 ± 0.06 | 1.04 [1.0-1.05] |
1.01 [0.7-1.4] |
0.84 | 1.0 [1.0-1.0] |
2.7 [2.3-2.9] |
0.0002 |
| ADA (U/L) | 29.5 ± 8.9 | 29.8 ± 10.4 | 28.3 ± 9.4 | 0.47 | 28.7 ± 10.7 | 50.6 ± 23.7 | <0.001 |
| OPN mRNA (fold change) (n = 13) |
1.0 ± 0.0 | 1.0 [1.0-1.0] |
2.2 [0.8-4.2] |
0.026 | 1.0 [1.0-1.0] |
0.4 [0.2-0.6] |
<0.001 |
| OPN (ng/mL) | 1.5 ± 0.6 | 1.6 ± 0.7 | 1.8 ± 0.9 | 0.25 | 1.7 ± 0.6 | 0.9 ± 0.5 | <0.001 |
| CD73 mRNA (fold change) (n = 13) |
1.0 ± 0.02 | 1.0 [1.0-1.01] |
1.05 [0.97-2.3] |
0.065 | 1.0 [1.0-1.01] |
0.8 [0.2-1.02] |
0.057 |
| Total CD73 (%) | 12.4 ± 9.1 | 9.6 [3.5-12.6] |
4.8 [1.5-13.6] |
0.76 | 12.3 [5.0-25.1] |
5.7 [2.5-9.2] |
0.0071 |
| Inosine (nmol) | 0.57 ± 0.1 | 0.59 ± 0.1 | 0.52 ± 0.1 | 0.0034 | 0.5 ± 0.2 | 0.8 ± 0.1 | <0.001 |
| IL-13 (pg/ml) | 26.3 ± 7.9 | 25.4 ± 8.9 | 23.4 ± 11.7 | 0.36 | 27.8 ± 6.6 | 10.9 ± 8.2 | <0.001 |
Data was presented as mean ± SD or median [IQR] as appropriate and indicated
ADA adenosine deaminase, IL interleukin, OPN osteopontin